CAR-T Cell Therapy: Revolutionizing Cancer Treatment with Engineered Immune Cells
DOI:
https://doi.org/10.54097/0t9r7b82Keywords:
CAR-T cell therapy, immunotherapy, cancer treatment.Abstract
CAR-T cell therapy, a revolutionary immunotherapy approach utilizes gene-engineered T cells to recognize and eliminate cancer cells. The CAR is engineered to recognize specific tumor-associated antigens, enabling T cells to effectively recognize and destroy cancer cells. Mostly, the cell for CAR-T cell therapy is collected from the patient which lead to a high individual. Then, the artificially engineered cells which express CAR, expand and culture in the laboratory. Finally, the CAR-T cells are sent back into the patient. This personalized therapy has shown remarkable success in treating hematological malignancies. Till now, there are shortages remaining in extending solid tumor application of it, since the potential side effects, including CRS and neurotoxicity. These challenges limit clinical usage and more waiting to be solved. In this paper, we aim to introduce CAR-T therapy and optimize CAR design, improve manufacturing processes, and explore combination therapies to enhance the efficacy and safety of it.
Downloads
References
Mitra A, Barua A, Huang L, Ganguly S, Feng Q and He B (2023) From bench to bedside: the history and progress of CAR T cell therapy. Front. Immunol.14: 1188049. Fangfang. Research on power load forecasting based on Improved BP neural network. Harbin Institute of Technology, 2011.
Ohta, K., Sakoda, Y. & Tamada, K. Novel technologies for improving the safety and efficacy of CAR-T cell therapy. Int J Hematol 117, 647–651 (2023).
HAN-QI WANG et al. Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine, [s. l.], v. 12, n.2173, p.2173, 2023.
Hilal, T., Mountjoy, L.J. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-CellTherapy. Curr. Oncol. Rep.25, 599–607 (2023).
Baker, D.J., Arany, Z., Baur, J.A. et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707–715 (2023).
Banerjee, R., Wang, V., Huang, CY. et al. Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy. Eur J Nucl Med Mol Imaging (2023).
Mukerjee, N., Maitra, S., Ghosh, A. et al. Impact of CAR-T cell therapy on treating viral infections: unlocking the door to recovery. Human Cell 36, 1839–1842 (2023).
Gu, T., Zhu, M., Huang, H. et al. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J. Zhejiang Univ. Sci. B 23, 793–811 (2022).
Kong, D., Yang, T., Geng, J. et al. Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy. J. Zhejiang Univ. Sci. B 23, 876–880 (2022).
Bixby, T.J., Brittle, C.J., Mangan, P.A. et al. Patient Perceptions of CAR-T Therapy in the USA: Findings from In-Depth Interviews. Oncol Ther 11, 303–312 (2023).
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
